Third, clinical practice targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) has shown that TME heterogeneity is a core factor affecting the efficacy of tumor immunotherapy. Here, PDCD1 is linked to neoplasm.